These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9737881)

  • 21. Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients.
    Abbate I; Romano M; Longo R; Cappiello G; Lo Iacono O; Di Marco V; Paparella C; Spano A; Capobianchi MR
    J Med Virol; 2003 Aug; 70(4):581-7. PubMed ID: 12794720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional expression of human type I interferon receptors in the mouse liver.
    Tochizawa S; Muraguchi M; Ohmoto Y; Oga K; Mori T
    Biochem Biophys Res Commun; 2006 Jul; 346(1):61-6. PubMed ID: 16750512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-induced association of the type I interferon receptor components.
    Cohen B; Novick D; Barak S; Rubinstein M
    Mol Cell Biol; 1995 Aug; 15(8):4208-14. PubMed ID: 7623815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta.
    Platis D; Foster GR
    J Interferon Cytokine Res; 2003 Nov; 23(11):655-66. PubMed ID: 14651780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of the type I interferon receptor and the interferon-induced Mx protein in human endometrium during the menstrual cycle.
    Ozaki T; Takahashi K; Kanasaki H; Iida K; Miyazaki K
    Fertil Steril; 2005 Jan; 83(1):163-70. PubMed ID: 15652903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding and activity of all human alpha interferon subtypes.
    Lavoie TB; Kalie E; Crisafulli-Cabatu S; Abramovich R; DiGioia G; Moolchan K; Pestka S; Schreiber G
    Cytokine; 2011 Nov; 56(2):282-9. PubMed ID: 21856167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptors for human interferon alpha on bovine cells: specificity and tissue distribution.
    Chambers PJ; Saltis J; Alin P; Wright A; Linnane AW; Cheetham BF
    Immunopharmacol Immunotoxicol; 1990; 12(3):513-25. PubMed ID: 2148343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon at 50: new molecules, new potential, new (and old) questions.
    Langer JA
    Sci STKE; 2007 Sep; 2007(405):pe53. PubMed ID: 17895481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human interferons alpha, beta and omega.
    Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
    Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
    Lamken P; Lata S; Gavutis M; Piehler J
    J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shared receptor components but distinct complexes for alpha and beta interferons.
    Lewerenz M; Mogensen KE; Uzé G
    J Mol Biol; 1998 Sep; 282(3):585-99. PubMed ID: 9737924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reconstitution of a high affinity binding site for type I interferons.
    Russell-Harde D; Pu H; Betts M; Harkins RN; Perez HD; Croze E
    J Biol Chem; 1995 Nov; 270(44):26033-6. PubMed ID: 7592797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the alpha subunit of the IFN-alpha receptor. Evidence of N- and O-linked glycosylation and association with other surface proteins.
    Platanias LC; Pfeffer LM; Cruciani R; Colamonici OR
    J Immunol; 1993 Apr; 150(8 Pt 1):3382-8. PubMed ID: 8468477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic activities of natural and synthetic type I interferons.
    Pfeffer LM
    Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. De novo design of nonpeptidic compounds targeting the interactions between interferon-alpha and its cognate cell surface receptor.
    Bello AM; Bende T; Wei L; Wang X; Majchrzak-Kita B; Fish EN; Kotra LP
    J Med Chem; 2008 May; 51(9):2734-43. PubMed ID: 18393399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The human interferon alpha species and receptors.
    Pestka S
    Biopolymers; 2000; 55(4):254-87. PubMed ID: 11169919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrinsic ligand binding properties of the human and bovine alpha-interferon receptors.
    Lim JK; Xiong J; Carrasco N; Langer JA
    FEBS Lett; 1994 Aug; 350(2-3):281-6. PubMed ID: 8070579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetylation-dependent signal transduction for type I interferon receptor.
    Tang X; Gao JS; Guan YJ; McLane KE; Yuan ZL; Ramratnam B; Chin YE
    Cell; 2007 Oct; 131(1):93-105. PubMed ID: 17923090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.